Shehada S-E et al. Feasibility and safety of combined percutaneous coronary intervention among highrisk patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2018;54:1052-9. Feasibility and safety of combined percutaneous coronary intervention among high-risk patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis Abstract OBJECTIVES: Recent reports indicated that percutaneous coronary intervention (PCI) may be correlated with increased mortality in patients undergoing transcatheter aortic valve implantation (TAVI). Therefore, we performed a meta-analysis to determine the feasibility and safety of combined PCI in high-risk patients with severe aortic stenosis undergoing TAVI. METHODS: A comprehensive literature search was performed using PubMed, Embase and the Cochrane Central Register of Controlled trials through June 2016.
INTRODUCTION
More than 40% of patients with aortic valve stenosis (AS) undergoing surgical aortic valve replacement (AVR) have concomitant coronary artery disease (CAD) [1] [2] [3] [4] . Current guidelines recommend complete myocardial revascularization for a > _70% reduction in the luminal diameter in major coronary arteries (Class IC) or a 50-70% reduction in the luminal diameter in major coronary arteries (Class IIaC) for patients undergoing conventional AVR and having significant CAD [5] [6] [7] . This is routinely achieved by simultaneous coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).
According to the EuroHeart survey and other series, 30% of patients with severe AS were not considered for treatment until transcatheter aortic valve implantation (TAVI) was introduced in clinical practice [8] . Currently, TAVI has been proven to be the treatment of choice in high-risk and elderly patients with symptomatic aortic valve disease [9] . The presence of encountered CAD and synchronous PCI procedures has been associated with the adverse procedural outcomes in conventional AVR [10] and recently also in TAVI [11, 12] . There has been a rapid, global expansion in the use of TAVI to treat AS in patients who are not candidates for conventional AVR. The efficacy of this technique has been successfully affirmed in randomized controlled trials [2] , and there is now a need to assess the best management strategy of patients with special conditions such as concomitant CAD.
Therefore, we performed a meta-analysis of the available literature. The purposes of the present study were (i) to assess the feasibility and safety of additional PCI among patients with severe AS undergoing TAVI; (ii) to investigate whether there is an increased periprocedural MACCE, including myocardial infarction, stroke, kidney injury, bleeding and vascular complications; and (iii) to define the risk-benefit ratio between staged or simultaneous PCI in CAD patients with severe AS undergoing TAVI.
MATERIALS AND METHODS

Literature search
A comprehensive literature search was performed using PubMed, Embase and the Cochrane Central Register of Controlled trials for published relevant articles (the last search update was 10 June 2016) using the following search keywords: 'transcatheter', 'aortic', 'valve', 'implantation' or 'replacement', 'corevalve' or 'sapien', 'stenosis' and 'PCI'. After initial screening based on titles and abstracts, the full texts of potentially relevant studies were retrieved for further evaluation. The reference lists of all relevant articles and general reviews on this topic were manually screened.
Study selection
As no randomized trials comparing TAVI versus TAVI+PCI approaches were available, we included cohort/observational studies with censored number of patients or the Kaplan-Meier curve. All forms of the TAVI technique and transcatheter heart valve (THV) were included. To maintain the consistency of measured end points, the current definitions of the Valve Academic Research Consortium (VARC)-2 were used as a guideline to assess the shortterm outcomes, when applicable [13] . The exclusion criteria were as follows: (i) reports in which subgroup outcome was not presented; (ii) if centres had published duplicate trials by accumulating the numbers of patients, only the most recent or complete studies with the largest numbers were included for qualitative appraisal; and (iii) any non-English review, comment and case report.
Data extraction and study quality
All screening activities were independently performed by 2 reviewers (C.M. and L.B.). The following information was extracted from each article: first author, publication year, country, city, enrolled period, treatment, patient number, Logistic EuroSCORE (%), Society of Thoracic Surgeons (STS) mortality score (%), SYNTAX score, TAVI access route, THV system, staged or singlestaged PCI, target vessel numbers, drug-eluting stent or bare metal stent used and VARC-2 end points. Any disagreements were resolved by consensus-based discussions. For trials included in this meta-analysis, if log hazard ratio or its variance was not explicitly presented, methods reported by Parmar et al. and Tierney et al. [14, 15] were used to extract estimates of these statistics.
Data analysis
The reported incidences and study-specific end points were calculated using odds ratio (OR) with 95% confidence intervals (CIs) for both the fixed-effects and random-effects models.
Heterogeneity between trials was quantified using the Cochrane Q-statistic and the I 2 -value. An I 2 -value >50% was considered substantial heterogeneity. We performed the random-effects model meta-analyses with the Mantel-Haenszel methods when interstudy heterogeneity existed; otherwise, we used the DerSimonian methods for random-effects model meta-analyses. We applied a forest plot to indicate the meta-analysis results. A P-value <0.05 for any test was considered to be statistically significant. All analyses were conducted using Review Manager Version 5.2 software (The Nordic Cochrane Centre, Copenhagen, Denmark).
RESULTS
Description of included trials
A total of 940 potentially relevant references or abstracts were identified. After exclusion of irrelevant or duplicate studies, 33 potentially relevant articles were evaluated in detail. Of these, 23 studies were excluded for reporting <10 patients. Three studies were excluded because PCI subgroup outcomes were not presented [16] [17] [18] . One study was excluded based on the study protocol [19] . One recent, prospective, case-control study including 10 consecutive patients treated with TAVI and PCI was excluded because some patients also had patent foramen ovale closure (2/10), atrial septal defect closure (1/10) or left atrial appendage occlusion (9/10) [20] . A flowchart summarizing the search results is provided in the Supplementary Material according to the PRISMA statement [21] . Finally, 5 studies were selected for this meta-analysis [12, [22] [23] [24] [25] . A summary of the baseline characteristics of the included patients is listed in Supplementary Material, Table S1 .
Assessment of mortality
The results are described in Fig. 1 . The pooled analysis of the 5 studies (with a total of 1634 patients) revealed no statistically significant difference in 30-day all-cause mortality between the patients who underwent TAVI and TAVI+PCI in the randomeffects model (OR 1.25, 95% CI 0.52-3.05; P = 0.62). Three trials provided data on the 30-day cardiovascular mortality rate. Patients treated with TAVI+PCI did not show significantly impaired 30-day cardiovascular mortality rate (OR 1.59, 95% CI 0.52-4.88; P = 0.41). For the 1-year mortality rate, all included studies yielded an estimated common OR of 1.16 (95% CI 0.85-1.59) with no significant effect on survival (P = 0.34). No significant difference in 30-day all-cause mortality was found between patients in the simultaneous TAVI+PCI group and the isolated TAVI group with a pooled OR of 1.73 (95% CI 0.57-5.22; P = 0.33). Notably, there was a statistically significant difference in 30-day all-cause mortality between patients in the staged TAVI+PCI group and the isolated TAVI group (OR 2.57, 95% CI 1.16-5.69; P = 0.02). Heterogeneity was found for some adverse events, which was possibly due to the use of different principles for synchronous PCI and TAVI in the studies.
Assessment of myocardial infarction rate
The results are described in Fig. 2 . Patients treated with a combination of TAVI+PCI had a significantly higher rate of myocardial infarction (OR 2.96, 95% CI 1.03-8.45; P = 0.04). There were no significant differences regarding periprocedural myocardial infarction (OR 3.25, 95% CI 0.87-12.22; P = 0.08) and spontaneous myocardial infarction (OR 4.65, 95% CI 0.89-24.31; P = 0.07). The differences in myocardial infarction rate demonstrated in both simultaneous and staged TAVI+PCI groups were not significantly different in the subgroup analysis (OR 2.84, 95% CI 0.85-9.5; P = 0.09; OR 4.29, 95% CI 0.89-20.6; P = 0.07, respectively).
Assessment of stroke and renal function
There were no significant differences between the two 2 groups regarding stroke and TIA (OR 0.74, 95% CI 0.29-1.93; P = 0.54) and renal failure AKIN 3 (OR 1.07, 95% CI 0.54-2.10; P = 0.86) (Fig. 3) . In addition, there were no significant differences in the simultaneous and staged TAVI+PCI groups regarding stroke, TIA and renal failure AKIN 3 (stroke and TIA: OR 1.41, 95% CI 0.35-5.72; P = 0.63; OR 0.51, 95% CI 0.07-3.89; P = 0.51, respectively. Renal failure AKIN 3: OR 1.65, 95% CI 0.75-3.64; P = 0.21; OR 0.64, 95% CI 0.17-2.41; P = 0.51, respectively).
Assessment of bleeding complications and accessrelated complications
The results are illustrated in Fig. 4 . There were no significant differences between the TAVI and TAVI+PCI groups regarding lifethreatening bleeding complications (OR 0.93, 95% CI 0.51-1.72; P = 0.82) and major access-related complications (OR 1.27, 95% CI 0.60-2.66; P = 0.53).
In the subgroup analysis, there were no significant differences regarding life-threatening bleeding complications (VARC-2) and major access-related complications (VARC-2) in both simultaneous and staged TAVI+PCI groups (life-threatening bleeding complications (VARC-2): OR 0.49, 95% CI 0.15-1.65; P = 0.25; OR 1.19, 95% CI 0.54-2.63; P = 0.66, respectively. Major accessrelated complications (VARC-2): OR 0.53, 95% CI 0.10-2.87; P = 0.46; OR 1.62, 95% CI 0.53-4.97; P = 0.40, respectively).
Other clinical outcomes
There were no significant differences between the two 2 groups regarding the need for new permanent pacemaker (OR 1.18, 95% CI 0.83-1.66; P = 0.36) and the rates of combined safety end point (VARC-2) (OR 0.82, 95% CI 0.49-1.36; P = 0.44).
DISCUSSION
The most important findings of this study were as follows: (i) combined PCI among high-risk patients with severe AS undergoing TAVI is feasible and reasonably safe; (ii) patients with PCI+TAVI exhibit higher myocardial infarction rates. Further potential complications from this combined procedure, such as stroke, kidney injury, bleeding and vascular complications, were not significantly different between groups; and (iii) patients treated with the staged procedure of TAVI and PCI had higher 30-day all-cause mortality as compared to those undergoing isolated TAVI.
Impact of coronary artery disease in transcatheter aortic valve implantation patients
Along with aortic valve disease, CAD is found in 50-70% of patients referred for TAVI [26, 27] . In a German TAVI registry, the existence of concomitant CAD was defined as the presence of stenosis with > _50% diameter on pre-TAVI angiography and/or previous treatment with PCI or CABG. Notably, 62.2% of 1382 patients had concomitant CAD and exhibited higher in-hospital mortality (10.0% vs 5.5%, P < 0.01). In addition, patients presenting with CAD demonstrated a higher rate of periprocedural cardiopulmonary resuscitation (7.8% vs 3.5%, P < 0.01) and lower unadjusted survival at 30 days as compared to the group without CAD (91.6% vs 94.7%, respectively, log-rank P = 0.04) [28] . A prospective registry of 445 patients with AS undergoing TAVI determined CAD severity according to the preoperative SYNTAX score (SS). At 1 year, CAD severity was associated with higher rates of cardiovascular mortality (no CAD: 8.6%, low SS: 13.6%, high SS: 20.4%; P = 0.029) [4] .
In the present analysis, neither 30-day all-cause mortality nor 1-year all-cause mortality was higher in the TAVI+PCI group, demonstrating the feasibility and safety of combined PCI among high-risk patients with severe AS undergoing TAVI. So far, there is no consensus on the indication for coronary intervention in the particular context of TAVI and how to manage significant CAD in this population. After evaluating a single-centre cohort of 263 consecutive patients, Van Mieghem et al. [18] emphasized that incomplete coronary revascularization at baseline is common in elderly patients undergoing TAVI for severe AS. When the revascularization strategy is based on practitioner consensus, complete revascularization is not a prerequisite for good medium-term prognosis. Several contemporary studies did not observe differences during clinical follow-up between patients with CAD irrespective of revascularization status [18, 23, 24] . In accordance with the reported experience, a French study from the Northern New England Cardiovascular Disease Study Group on 7584 patients undergoing conventional AVR corroborated that incomplete revascularization did not impact survival in octogenarians as opposed to patients <80 years of age. As this particular elderly population is at a high operative risk, it may be safer to consider limited coronary revascularization [29] .
Periprocedural complications
Myocardial infarction remains a serious adverse event after TAVI. Even though 2 studies found no events in both groups [22, 23] , our data showed a higher rate of myocardial infarction in TAVI+PCI patients. Notably, the higher incidence of periprocedural myocardial infarction in TAVI+PCI patients did not directly translate into a higher mortality at the 30-day or 1-year follow-up. While the reasons underlying this discrepancy cannot be easily identified, one possible explanation is that the TAVI+PCI procedure neutralized the net risk-benefit ratio. Additionally, other periprocedural complications such as stroke and TIA, kidney failure, bleeding and vascular complications occurred with comparable rates in both groups. These findings are not in accordance with previous reports, suggesting a higher perioperative risk of the combination of revascularization by CABG and AVR [10] .
Advantages of the simultaneous single-stage procedure
The timing for treating CAD in patients undergoing TAVI remains unknown. One of the important arguments as to whether or not to perform a staged PCI/TAVI is the local medical reimbursement policies. A staged approach with revascularization of significant coronary artery lesions prior to TAVI has some advantages, including reduced duration of the TAVI procedure, optimization of the contrast media volume used and a protective effect against the worsening of myocardial ischaemic burden, and haemodynamics including periods of hypotension (especially during rapid ventricular pacing) [22, 23] . Our analysis revealed that patients treated with the staged procedure of TAVI and PCI, but not with simultaneous TAVI and PCI, had higher 30-day all-cause mortality as compared to those undergoing isolated TAVI. Therefore, a simultaneous approach, performing PCI and TAVI in the same operative session, may be advantageous.
As compared to the staged approach, simultaneous PCI and TAVI are advantageous due to the relative reduction in arterial access with the inherent risk for vascular access complications and bleeding events and may reduce operational costs, while an additional invasive procedure can be avoided. Longer hospitalization not only leads to increased costs but is also associated with an increased risk of hospital-acquired infections and consequently may have negative implications on the prognoses, especially in octogenarians [30] , which may help to explain the statistically significant differences in 30-day all-cause mortality between patients undergoing staged TAVI+PCI and isolated TAVI.
Albeit persuasive, there are several limitations in this study, given that the included studies were all non-randomized and registry type with relatively small sample sizes. The TAVI procedures were discriminated between transfemoral, trans-subclavian and transapical approaches in the original studies, but the present analysis did not consider this heterogeneity, potentially hampering the generalizability of the results. Moreover, the multimodality of THV was employed in our study, but information regarding heterogeneity between the different THV procedures remains limited. Another limitation is the lack of data regarding the angina status of patients before and after PCI, which could not be identified easily and the fact that symptoms were attributed to the valvular disease or CADs. Finally, a nonpatient level-based analysis may represent another weakness. Randomized studies are required to test the current practice on myocardial revascularization for patients receiving transcatheter therapy of aortic valve disease [19] .
This systematic review of 5 clinical trials including 1634 patients suggested that (i) PCI among high-risk patients with severe AS undergoing TAVI is feasible and safe; (ii) differences of 30-day all-cause mortality between patients undergoing staged TAVI+PCI and isolated TAVI deserve more attention in future Figure 4 : Forest plots of the odds ratio of life-threatening bleeding complications (VARC-2) and major access-related complications (VARC-2) after combined PCI among high-risk patients with severe aortic valve stenosis undergoing TAVI versus isolated TAVI. CI: confidence interval; PCI: percutaneous coronary intervention; TAVI: transcatheter aortic valve implantation; VARC-2: Valve Academic Research Consortium-2. study design; (iii) no increase was found in stroke rate, acute kidney injury, bleeding or vascular complications; and (iv) the timing of elective PCI in patients planned for TAVI is essential in the individual decision-making process within the interdisciplinary cardiac team. The simultaneous treatment of significant coronary artery lesions may be preferred in selected patients undergoing TAVI.
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